Read everything here.Cancer Money Horoscope TodayYou will receive guidance from seniors at work, maintaining a notable ...

The RESOLVE trial is a Phase 1b/2a, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of EP-104GI in adults with histologically ...

A Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...

The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...

The European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one year of age. Specifically, the approval covers children aged one to ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological <a target=_blank ...

Allergic reactions come in all varieties. One can even trigger a digestive disease called Eosinophilic Esophagitis, which ...

The investigational monoclonal antibody cendakimab significantly improved symptoms and reduced esophageal eosinophils in ...

Speakers were compensated for their participation at this event. The dynamic treatment landscape for eosinophilic oesophagitis (EoE) continues to emphasise symptom relief, often neglecting the ...